Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Diabetes Care 36 , S145S148 (2013)
Subcutaneous administration achieves brain concentrations twice plasma levels (t 1/2 ~10.5 hr) with no toxicity observed at 15 the therapeutic dose in rats
Lipid profile improvements (TRIUMPH-4): Non-HDL cholesterol: Clinically meaningful reduction Triglycerides: Significant reduction hsCRP (inflammatory marker): Significant reduction HDL cholesterol: Not significantly improved (consistent with Phase 2 findings) The triglyceride reduction is particularly notable and likely related to glucagon receptor activation, which enhances fat oxidation
The association between melanosis coli and the use of cathartics that contain the active ingredient, anthraquinone, has been established
The mean differences between left and right thalamic GSH were small and non-significant in all groups (HC: p = 0.570
Moreover, depressed patients show a reduction in synaptic density proteins in response to stress (Kang et al., 2012)
